Amendment to Development and Marketing Agreement between Boehringer Ingelheim International GmbH and InterMune, Inc.
Contract Categories:
Business Operations
›
Development Agreements
Summary
Boehringer Ingelheim International GmbH and InterMune, Inc. have agreed to amend their existing Development and Marketing Agreement dated March 23, 2001. The amendment expands the scope of the agreement to include non-Hodgkin's Lymphoma (NHL) as a covered field and indication, and adds a new clinical protocol (GINHL-001) to the agreement. Both parties have accepted these changes by signing this letter, which serves as a formal amendment to the original contract.
EX-10.54 11 a2082633zex-10_54.htm EXHIBIT 10.54
EXHIBIT 10.54
[BOEHRINGER
INGELHEIM LOGO]
| Boehringer Ingelheim International GmbH - 55216 Ingelheim am Rhein InterMune Pharmaceuticals 3280 Bayshore Blvd Brisbane, CA 94005 U.S.A. | Boehringer Ingelheim International GmbH | |
1 July 2002 | ||
Development and Marketing Agreement dated March 23, 2001 (Agreement) | Our reference CD Dr.Mi-mw | |
Dear Sirs | Dr. David Mitchard Phone +49/61 32/77-34 08 Fax +49/61 32/77-35 83 E-Mail ***@*** | |
Words and expressions defined or interpreted in the Agreement shall have the same meanings and interpretations when used in this letter. We propose the following changes to the Agreement: | Binger Strasse 173 55216 Ingelheim am Rhein Germany Phone +49/61 32/77-0 Fax +49/61 32/72-0 www.boehringer-ingelheim.com |
- 1.10
- The definition Field is extended to include non-Hodgkin's Lymphoma (NHL).
- 1.22
- The definition New Indications is extended to include NHL.
- 1.25
- The definition Protocols is extended to include the clinical protocol
entitled
"GINHL-001"
which InterMune sent to BII with a letter dated May 30, 2002.
If you agree with the above, please signify your acceptance by signing and
returning one original of this letter.
| Yours faithfully BOEHRINGER INGELHEIM INTERNATIONAL GmbH ppa. /s/ Dr. Mitchard Jesse Dr. Mitchard Jesse | Accepted for and on behalf of InterMune, Inc. /s/ John J. Wulf John J. Wulf by: Sr. V.P. of Corporate Development Date: July 9, 2002 | Board of Managing Directors Prof. Dr Dr h.c. Rolf Krebs (Chairman) Dr Alessandro Banchi Dr Dr Andreas Barner Dr Hans-Jürgen Leuchs Prof. Dr Marbod Muff Seat Ingelheim am Rhein Commercial Register Bingen HR B 1063 Deutsche Bank AG BLZ 550 700 40 Account No. 0122 580 Swift: DEUTDE5M |
